Skip to content
ChickenStockChickenStock
ResearchACAD
Acadia Pharmaceuticals logo

Acadia Pharmaceuticals (ACAD) stock

NASDAQ

$18.31-1.93%(-0.36)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

8.72x

P/B

2.28x

P/S

2.63x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 22.6% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 5, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

10 SEC filings
  • Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · Oct 30, 2026Open-market sale3,321 shares · $69K
    Avg. price $20.8871,322 shares held after
  • Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · Oct 15, 2026Grant or award6,815 shares · $0
    Avg. price $074,643 shares held after
  • Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · Aug 6, 2026Open-market sale14,292 shares · $418K
    Avg. price $29.2194
    Show 2 price lots
    • 9,292 shares × $29.3375$273K
    • 5,000 shares × $29$145K
  • Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · Aug 6, 2026Option exercise14,292 shares · $255K
    Avg. price $17.8482,120 shares held after
  • Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · Aug 5, 2026Open-market sale5,849 shares · $170K
    Avg. price $29.002967,828 shares held after
  • Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER · Aug 5, 2026Option exercise5,849 shares · $104K
    Avg. price $17.8473,677 shares held after
  • Thompson Elizabeth H.Z.EVP, Head of Research & Dev · Jul 30, 2026Open-market sale16,558 shares · $433K
    Avg. price $26.1301
    Show 2 price lots
    • 16,508 shares × $26.13$431K
    • 50 shares × $26.17$1K
  • Thompson Elizabeth H.Z.EVP, Head of Research & Dev · Jul 29, 2026Option exercise32,272 shares
    35,552 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Acadia Pharmaceuticals (ACAD) stock information

NASDAQ

Acadia Pharmaceuticals (ACAD) is listed on NASDAQ. Its market capitalization is about $3.2B. On trailing-twelve-month earnings the P/E ratio is 8.72, and the P/B ratio is 2.28. Return on equity is 26.2%. These figures are computed in-house from official filings and are reference information only.

Acadia Pharmaceuticals — frequently asked questions

What is the P/E ratio of Acadia Pharmaceuticals (ACAD)?
On a trailing-twelve-month basis, ACAD trades at a P/E ratio of 8.72. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Acadia Pharmaceuticals?
ACAD has a market capitalization of about $3.2B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.